Claim OwnershipPharmaceutical Executive
Subscribed: 159Played: 3,690
Subscribe
Description
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
317 Episodes
Reverse
In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims about its bladder cancer therapy Anktiva, Merck agrees to acquire Terns Pharmaceuticals in a $6.7 billion deal while Shionogi moves to take full ownership of the Shionogi-Apnimed Sleep Science joint venture, and a new commentary examines the structural pricing problem sitting at the center of the GLP-1 access debate.
In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, Quotient Therapeutics enters a multi-year research collaboration with Merck to discover novel drug targets in inflammatory bowel disease, and Gilead Sciences agrees to acquire privately held Ouro Medicines in a deal valued at up to $2.18 billion.
In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase up to one million shares at a potentially below-market price, the FDA grants expanded approval to Rhythm Pharmaceuticals' Imcivree as the first approved treatment for acquired hypothalamic obesity, and a new commentary makes the case that AI-powered roleplay data is an untapped source of commercial intelligence for pharma field teams.
In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire Azstarys from Corium Therapeutics, the FDA grants accelerated approval to Wegovy HD, a higher-dose version of Novo Nordisk's semaglutide injection, supported by Phase III data showing roughly 21% mean weight loss, and an analysis on agentic AI and what it means for commercial operations in life sciences.
The episode explores how regulatory signals across drug approvals, trade policy, AI governance, and drug pricing shape business strategy and investor decisions before formal rules are ever finalized.
In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two biotech companies focused on next-generation T-cell engager therapies close significant funding rounds, and Pharmaceutical Executive sits down with Jeanne Marrazzo of the Infectious Diseases Society of America on the worsening U.S. measles outbreak and what it means for the future of vaccine confidence.
In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and halts its policy changes, a new analysis breaks down what recent Gartner predictions on AI mean for healthcare marketers, and the FDA approves Icotyde as the first oral targeted therapy for moderate-to-severe plaque psoriasis.
In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl Therapeutics enters a licensing agreement with PRG-ST to advance a progerin-targeting therapy for progeria, and a new analysis examines the innovations, integration challenges, and early hurdles shaping the emerging biotech landscape.
In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.
Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.
In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Novo Nordisk responds to an FDA warning letter stemming from a 2025 inspection of its U.S. headquarters, and Pharmaceutical Executive's latest analysis examines the state of the biopharma industry as it navigates a period of cautious momentum.
In today's Pharmaceutical Executive Daily, the FDA approves leucovorin as the first-ever treatment for an ultra-rare genetic condition called cerebral folate transport deficiency, Enhertu receives FDA Priority Review for HER2-positive early breast cancer in the post-neoadjuvant setting, and a new commentary argues that AI has fundamentally changed how healthcare communicators must think about content strategy.
In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under a year, major deal activity including a GSK and Alfasigma licensing agreement along with Servier’s $2 billion acquisition of Day One Pharmaceuticals, and Ipsen withdraws Tazverik from the market following emerging clinical trial data.
In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intelligence and large language models reshape pharmacovigilance and drug safety monitoring, and Eli Lilly launches a new Employer Connect platform to expand obesity treatment coverage options.
In today’s Pharmaceutical Executive Daily, Antengene and UCB enter a billion-dollar global licensing agreement for a bispecific T-cell engager, Teva signs a $400 million strategic growth capital agreement with Blackstone Life Sciences, and industry leaders explore the technological renaissance driven by AI integration.
Alice Valdur Curan discusses how the industry continues to strategize around this complicated order.
In today’s Pharmaceutical Executive Daily, industry leaders examine how to measure AI’s return on investment across the life sciences value chain, Novo Nordisk commits $506 million to expand its Ireland manufacturing facility, and Bavarian Nordic CEO Paul Chaplin announces plans to step down.
In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older, Sogroya becomes the first and only weekly long-acting growth hormone approved for pediatric use, and experts examine how real-world data strengthens natural history disease research.
In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry leaders explore the expansion of direct-to-consumer HIV prevention strategies, and Dupixent gains FDA approval for allergic fungal rhinosinusitis.
Comments
Download from Google Play
Download from App Store
United States